Evidence map›Paper›PMID 26910821›Full record

ArticleMolecular neurobiology2017

Mitochondrial Proteome Changes Correlating with β-Amyloid Accumulation.

Katalin Völgyi, Krisztina Háden, Viktor Kis, Péter Gulyássy, Kata Badics, Balázs András Györffy, Attila Simor, Zoltán Szabó, Tamás Janáky, László Drahos and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Katalin VölgyiMTA-ELTE NAP B Laboratory of Molecular and Systems Neurobiology, Hungarian Academy of Sciences and Eötvös Loránd University, Budapest, Hungary. katvolgyi@gmail.com.
Krisztina HádenLaboratory of Proteomics, Eötvös Loránd University, Budapest, Hungary.
Viktor KisDepartment of Anatomy, Cell and Developmental Biology, Eötvös Loránd University, Budapest, Hungary.
Péter GulyássyLaboratory of Proteomics, Eötvös Loránd University, Budapest, Hungary.
Kata BadicsLaboratory of Proteomics, Eötvös Loránd University, Budapest, Hungary.
Balázs András GyörffyLaboratory of Proteomics, Eötvös Loránd University, Budapest, Hungary.
Attila SimorLaboratory of Proteomics, Eötvös Loránd University, Budapest, Hungary.
Zoltán SzabóMedical Chemistry Department, University of Szeged, Szeged, Hungary.
Tamás JanákyMedical Chemistry Department, University of Szeged, Szeged, Hungary.
László DrahosMTA-TTK NAP B MS Neuroproteomics Research Group, Research Center for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
Árpád DobolyiMTA-ELTE NAP B Laboratory of Molecular and Systems Neurobiology, Hungarian Academy of Sciences and Eötvös Loránd University, Budapest, Hungary.
Botond PenkeMedical Chemistry Department, University of Szeged, Szeged, Hungary.
Gábor JuhászLaboratory of Proteomics, Eötvös Loránd University, Budapest, Hungary.
Katalin Adrienna KékesiLaboratory of Proteomics, Eötvös Loránd University, Budapest, Hungary.
Eötvös Loránd University · HUUniversity of Szeged · HUHungarian Academy of Sciences · HUHUN-REN Research Centre for Natural Sciences · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a multifactorial disease of wide clinical heterogenity. Overproduction of amyloid precursor protein (APP) and accumulation of β-amyloid (Aβ) and tau proteins are important hallmarks of AD. The identification of early pathomechanisms of AD is critically important for discovery of early diagnosis markers. Decreased brain metabolism is one of the earliest clinical symptoms of AD that indicate mitochondrial dysfunction in the brain. We performed the first comprehensive study integrating synaptic and non-synaptic mitochondrial proteome analysis (two-dimensional differential gel electrophoresis (2D-DIGE) and mass spectrometry) in correlation with Aβ progression in APP/PS1 mice (3, 6, and 9 months of age). We identified changes of 60 mitochondrial proteins that reflect the progressive effect of APP overproduction and Aβ accumulation on mitochondrial processes. Most of the significantly affected proteins play role in the mitochondrial electron transport chain, citric acid cycle, oxidative stress, or apoptosis. Altered expression levels of Htra2 and Ethe1, which showed parallel changes in different age groups, were confirmed also by Western blot. The common regulator bioinformatical analysis suggests the regulatory role of tumor necrosis factor (TNF) in Aβ-mediated mitochondrial protein changes. Our results are in accordance with the previous postmortem human brain proteomic studies in AD in the case of many proteins. Our results could open a new path of research aiming early mitochondrial molecular mechanisms of Aβ accumulation as a prodromal stage of human AD.

Indexed as

Amyloid beta-PeptidesAnimalsBrainHumansMiceMice, Inbred C57BLMice, TransgenicMitochondriaProteomeAmyloid beta-PeptidesProteomeAlzheimer’s disease (AD)APP/PS1 mouse modelNon-synaptic mitochondriaSynaptic mitochondriaβ-Amyloid (Aβ)

Identifiers

PMID26910821
OpenAlexW2283969971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.